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The delay of aging and healthy life exten-
sion is a primary concern of modern
gerontological research. Based on theoret-
ical assumptions and empirical findings, a
number of bioactive agents have been pro-
posed as promising “anti-aging” (geropro-
tective) preparations (de Magalhães et al.,
2012; Kennedy and Pennypacker, 2014).
Usually, the substance is considered to
have aging-modulating activity if its effi-
ciency can be confirmed both in vitro
and in vivo. In the first step of screening,
a hypothetical geroprotective compound
(e.g., antioxidant known to play a key
role in ROS scavenging) is examined in
in vitro models. If its effectiveness is con-
firmed, then its aging-modulating prop-
erties are studied in experimental in vivo
models. In the case where supplementa-
tion of experimental animals with this
agent causes life extension, it advertised as
anti-aging drug. A logic discrepancy, how-
ever, can be generated between these two
steps. Indeed, even if some substance is
highly effective in in vitro model due to
influencing a specific age-related pathway,
its life-extending effects in animal models
might be caused by unspecific (hormetic)
mechanisms.
Hormetic responses are commonly
referred to as stimulatory effects occur-
ring in response to low levels of exposure
to stressors or agents that are harmful
at high levels of exposure. The prevailing
hypothesis explaining the hormetic phe-
nomenon is that a low dose of a toxic
agent induces damage; following this dam-
age, a repair response is initiated which
result in a slight overcompensation to the
disruption of homeostasis, i.e., a general
response of the organism (Calabrese,
2013). According to this hypothesis, vari-
ous mild stresses and low-dose pharmaco-
logical treatments may cause rather similar
beneficial effects because these effects are
not mediated by specific receptors. There
is a large corpus of data demonstrat-
ing that hormesis is implicated in health
and disease across various species includ-
ing human beings (Rattan and Le Bourg,
2014). Longevity hormesis was repeat-
edly obtained for a number of obviously
harmful substances including herbicides,
pesticides, heavy metals, and hydrocar-
bons (Neafsey, 1990). The hormetic model
of dose response is usually described as
U-shaped curve ranging from impairment
at levels of deficient intake, to optimal
function at intermediate levels, and to tox-
icity at excessive intake levels (Calabrese,
2013). All prospective aging-modulating
agents are essential nutrients necessary
to support health and well-being. These
dietary components including minerals,
trace elements, vitamins and antioxi-
dants, however, similarly to hormetic com-
pounds (“hormetins”) all exhibit toxic
effects at excess levels, i.e., they show typi-
cal hormetic dose response (Rattan, 2008).
Indeed, while the moderate daily levels of
vitamins and minerals are both required
and beneficial, their excessive dietary lev-
els are known to cause hypervitaminosis,
tissue mineralization, or electrolyte imbal-
ance (Hayes, 2007). The excessive intake
of antioxidants and hormones is known
to destroy delicate control mechanisms
of homeodynamics, and it seems there-
fore unlikely that they have a long-term
beneficial impact (Goto, 2004).
Furthermore, both presumably aging-
modulating effects and hormetic effects
do not preclude the coexistence of toxic-
ity and other adverse outcomes. The pre-
dominance of beneficial (life-extending)
or deleterious effects may vary not only
with dose but also with species, gen-
der, age, stage of life, disease or disability
(Minois, 2000). In some cases, life exten-
sion caused by both hormetins and gero-
protectors may be accompanied by side
effects such as impairment of reproduc-
tive and immune functions, as well as
stress resistance (Matsagas et al., 2009; Saul
et al., 2013; McClure et al., 2014). In addi-
tion, pharmaceutical interventions can act
as caloric restriction (CR) mimetics due
to the suppression of the appetite, and
their life-extending effects may be caused,
at least partially, by the CR-inducing
hormetic response (Masoro, 2007).
Given all these consideration, it can be
concluded that similarity may exist in the
mode of action between hormetins and
geroprotectors. Currently, however, these
are no valid criteria to distinguish mech-
anistic pathways between them. Such cri-
teria were first proposed and efforts were
made to validate them as early as in the
60–70 s of the last century in works of
George A. Sacher which distinguished the
life-extending effects of substances acting
by a “proper action” (a specific role of
these agents in reducing the accumula-
tion of age-associated lesions or protect-
ing against age-related disorders) from the
hormetic (non-specific) effects (Sacher,
1977). According to this point of view,
a hormetic response is a function of the
state of an organism, rather than a kind
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of the stimulant. Furthermore, it has been
suggested that such effect could only be
observed in depressed or ill individuals
and, therefore, hormesis would not result
in an increase of maximal life span but
would serve only to enable the animal to
approach its potential longevity due to
nullification of several adverse environ-
mental effects (Sacher and Trucco, 1962).
In addition, Sacher and Trucco postulated
that hormesis can be found only if con-
trol animals are short-lived. In subsequent
studies, however, it became clear that effi-
ciency of geroprotectors is also strongly
dependent on the viability of control pop-
ulation (Izmaylov and Obukhova, 1996).
A tendency to increase the mean life span
rather than themaximal life span was simi-
larly found for both hormetic (Goto, 2004)
and geroprotective (Bonnefoy et al., 2002;
Spindler, 2003) actions. Moreover, the
magnitude of the life-extending effects of
geroprotectors is consistent with that seen
for hormetins. In most cases, the maxi-
mum magnitude of such effects does not
exceed 20–30% (Frolkis and Muradian,
1991; Olshansky et al., 2002; Spindler,
2003).
Sacher also assumed that hormetically-
induced life extension is distinct from that
caused by “proper actions” in the shape of
age-specific logarithmic mortality curves
and their Gompertz approximations (the
exponential equation to approximate the
probability of death as a function of age).
For example, low-dose radiation expo-
sure, according to his point of view, leads
to decrease of the Gompertz intercept
(frailty), while caloric restriction (“proper
action,” by Sacher) causes a decrease of
the Gompertz slope (rate of senescence)
(Sacher, 1977). More recent studies, how-
ever, were unable to confirm such assump-
tion. For example, Doubal and Klemera
(1999) by analyzing survival data from
many studies revealed that the effects of
caloric restriction as well as antioxidants
on the behavior of mortality curves in
mice and rats do not indicate that these
treatments alter the rates of aging.
In summarizing these findings, it
becomes obvious that Sacher’s crite-
ria of mechanistic demarcation between
the hormetically-induced and “proper
action”-induced life-extending effects are
likely doubtful. Indeed, the efficiency of
anti-aging drugs is generally attributed
to their specific geroprotective activities.
This explanation, however, ignores the fact
that aging process, rather than changes in
individual cells, tissues, or organs, may
be more a function of the deterioration
of integrative mechanisms, for instance,
in the central nervous system (Shock,
1977). Since aging process is characterized
by increased homeodynamic imbalance
and progressive impairment of organism’s
adaptive abilities, the hormetic stimula-
tion of the organism’s maintenance and
repair pathways known to be regulated by
integrative mechanisms (Minois, 2000),
may induce the body’s own ability to
combat stresses, including aging. Thus,
although the potential aging-modulating
drugs can really affect some specific
molecular and cellular pathways related
to aging, their life-prolonging effects may
likely be explained by unspecific hormetic
responses. It can be hypothesized that cer-
tain compound can cause life-extending
effect because it was applied within the
optimal hormetic response zone for this
substance. At the same time, when used
in high dose, it may exhibit adverse effects
similarly to all conventional toxicants.
Indeed, U-shaped (hormetic-like) dose–
response relationship for health benefits
has been repeatedly demonstrated for a
variety of prospective aging-modulating
compounds. For example, in a variety
of clinical trials it has been shown that
high doses of antioxidant supplements
may be associated with unwanted conse-
quences for the health and higher all-cause
mortality, especially in well-nourished
populations (Calabrese et al., 2010; Dolara
et al., 2012; Goyal et al., 2013; Bjelakovic
et al., 2014).
In the consideration of life-extending
effects of aging-modulating drugs, a logi-
cal error can occur as a result of reduction-
ist thinking peculiar to gerontologists in
the middle of the last century when major
aging theories including the free radical
theory of aging were proposed. From the
reductionist point of view, the organism
was considered as a sum of relatively inde-
pendent processes and mechanical com-
ponents, and interventions designed to
prolong life were seen as those being sim-
ilar to car repairing. If this were indeed
the case, then it would be possible to slow
the rate of aging by affecting molecular
pathways that influence specific aspects of
aging, analogous to how antioxidants can
slow down the rate of aging of plastic.
However, by summarizing the accumu-
lated information, one can conclude that
a reductionist approach in experimental
gerontology has proved rather ineffective
until now. This is not surprising, since
aging is a classic “complex trait,” in other
words, a trait that is influenced by a plu-
rality of genetic pathways. For example,
Rose and Burke (2011) reported, based
on their own genome-wide research in
Drosophila and findings by other authors,
that hundreds of genes are involved in
the control of aging. Therefore, it seems
very difficult, if not impossible, to develop
effective pharmaceutical interventions that
may slow aging and extend longevity by
targeting single genetic pathways.
On the contrary, more modern sys-
temic (“holistic”) thinking considers the
organism as a whole (Fardet and Rock,
2014). Taking into account the complexity
of the aging process, the systemic approach
addressed primarily to central regulation
mechanisms seems more appropriate to
developing aging-modulating treatments.
From a systemic point of view, aging is not
a disease in the sense of being caused by
disturbance in several specific pathway(s),
but is rather an inevitable consequence
of realization of some (probably still
substantially unknown) central regulatory
processes making the organism more vul-
nerable to disease with age. According to
these conceptual frameworks, aging pro-
cess is not primarily a result of accumu-
lation of stochastic damage but is rather
a co-product of developmentally regulated
processes (de Magalhães, 2012).
One potential mechanism of central
regulation of the whole life cycle including
aging is a process of epigenetic con-
trol of gene expression having impor-
tant features in the given context. Indeed,
it is: (1) potentially adaptive; (2) link-
ing development and aging; (3) general-
izing at the whole-organism level. It is
noteworthy that modulation of epigenetic
processes may amazingly influence the
longevity. For example, in social insects
queens and workers sometimes exhibit
a 100-fold difference in longevity, with
reproductive queens having much longer
lifespan than non-reproductive workers.
There is emerging evidence that extremely
long-lived queen phenotype is driven by
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epigenetic mechanisms of gene regula-
tion (Welch and Lister, 2014). Epigenetic
mechanisms are also likely involved in
the hormetic phenomenon (Vaiserman,
2011), and treatment with epigenetic
drugs, e.g., pharmacological inhibitors of
histone deacetylases, can lead to a signif-
icant life extension in model organisms
(Vaiserman and Pasyukova, 2012).
In conclusion, the transition from
reductionism to a system-oriented per-
spective (Russo et al., 2014) and utiliz-
ing the systematic approaches in modern
biogerontology may likely result in devel-
oping novel aging-modulating treatment
strategies and provide new ways to extend
human health span.
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